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Abstract
Background: Thrombus formation is a key step in the pathophysiology of acute ischemic stroke and results from the
activation of the coagulation cascade. Thrombin plays a central role in this coagulation system and contributes to thrombus
stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa). TAFIa counteracts endogenous fibrinolysis at
different stages and elevated TAFI levels are a risk factor for thrombotic events including ischemic stroke. Although
substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the
consequences of TAFI inhibition in animal models of cerebral ischemia are still lacking. In the present study we analyzed
stroke development and post stroke functional outcome in TAFI-/- mice.
Methodology/Principal Findings: TAFI-/- mice and wild-type controls were subjected to 60 min transient middle cerebral artery
occlusion (tMCAO) using the intraluminal filament method. After 24 hours, functional outcome scores were assessed and infarct
volumes were measured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices. Hematoxylin and eosin (H&E) staining
was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by
immunoblot. Infarct volumes and functional outcomes did not significantly differ between TAFI-/- mice and controls (p.0.05).
Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. TAFI
deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO.
Conclusion: Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after
ischemic brain challenge.
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Introduction
The majority of ischemic strokes are caused by thromboembolic
occlusion of brain arteries [1]. Consequently, thrombolysis using
recombinant tissue plasminogen activator (rt-PA) is an established
therapy during the first 4.5 h after stroke onset but efficacy is only
moderate at best and about 90% of all stroke patients must be
excluded from rt-PA treatment due to numerous contraindications
[2,3]. Current strategies for secondary stroke prevention comprise
platelet inhibitors and long-term anticoagulation with warfarin in
the case of cardioembolic stroke. However, as a major drawback
these substances are all associated with increased bleeding
complications [4]. Hence, there is a significant unmet medical
need for more effective and safer therapies in patients with acute
or recurrent stroke.
Two distinct pathways of blood coagulation can initiate the
formation of a fibrin thrombus, the extrinsic and the intrinsic
pathway [5]. Both are activated in a ‘‘waterfall-like’’ manner
involving a series of trypsin-like serine proteases such as the tissue
factor (TF)/FVIIa complex (extrinsic pathway) or FXII (intrinsic
pathway) finally culminating in the generation of thrombin [6].
Thrombin is considered a key component of blood coagulation
[7]: It can initiate clotting by activating FV and FVIII, platelets,
and platelet-bound FXI. Moreover, the conversion of prothrom-
bin to thrombin by FXa and FVa further propagates coagulation.
Finally, thrombin is critically involved in thrombus stabilization
via thrombin-dependent FXIIIa-driven cross-linking of the fibrin
network and activation of thrombin-activatable fibrinolysis
inhibitor (TAFI). Activated TAFI (TAFIa) is part of a highly
dynamic system that downregulates fibrinolysis. Activation occurs
with high doses of thrombin in the absence of thrombomodulin in
the setting of the intrinsic pathway of coagulation, or with low
concentrations of thrombin in complex with thrombomodulin [8].
TAFIa acts through removing carboxy-terminal lysine residues of
partially degraded fibrin, leading to elimination of plasminogen
binding sites, inhibition of plasminogen activation and impaired
fibrinolysis [8,9]. Several polymorphisms in the human TAFI gene
have been identified that influence TAFI antigen levels [10,11]
and elevated serum TAFI is a risk factor for deep vein thrombosis
[12] and coronary artery disease [13]. In contrast, available data
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on the role of TAFI in cerebral ischemia are limited but its
function as an endogenous fibrinolysis inhibitor and the observa-
tion that TAFI-deficient (TAFI-/-) mice do not show abnormal
bleeding [14,15] renders TAFI an attractive therapeutic target in
different thromboembolic disorders including stroke. In the
present study we assessed stroke development, intracerebral fibrin
formation and post stroke functional outcome in TAFI-/- mice.
Results
The middle cerebral artery (MCA) was occluded with a silicon-
coated filament for 60 min (transient middle cerebral artery
occlusion, tMCAO) to induce focal cerebral ischemia in mice
[16,17]. After advancing the filament to the origin of the MCA the
decrease in regional cerebral blood flow (rCBF) was similar
between wild-type mice and TAFI-/- mice (8.364.2% vs.
10.261.5% of baseline levels; p.0.05) (Figure 1A). Ten minutes
after removal of the filament (reperfusion) rCBF in the MCA
territory was reconstituted to ,70% of baseline levels and again
did not significantly differ between the two mouse groups
(69.568.3% vs. 73.4610.1% of baseline levels; p.0.05)
(Figure 1A). These findings exclude that TAFI-/- mice show
preformed rCBF alterations related to the genotype and prove that
MCA occlusion and reperfusion were sufficient in our model.
Along these lines, no aberrations in the cerebral vasculature were
observed in TAFI-deficient mice as assessed by transcardial ink
perfusion (Figure 1B).
As a next step, we determined infarct sizes and the extent of
neuronal damage in TAFI-/- mice and controls. 24h after tMCAO
no significant differences in infarct volumes were observed
between the two groups as revealed by 2,3,5-Triphenyltetrazo-
liumchloride (TTC) staining and successive infarct planimetry
(91.4621.5 mm3 vs. 95.6627.2 mm3; p.0.05) (Figure 2A).
In line with these findings, H&E staining confirmed widespread
ischemic neurodegeneration in both groups which regularly
expanded to the basal ganglia and the neocortex (Figure 2A).
Figure 1. rCBF and the anatomy of the cerebral vasculature do not differ between TAFI-/- mice and controls. (A) Determination of
regional cerebral blood flow (rCBF) using Laser Doppler flowmetry before the occlusion of the middle cerebral artery (baseline), 10 min after the
occlusion (ischemia) and again 10 min after the removal of the filament (reperfusion) in TAFI-/- mice and wild-type controls (n = 4/group). No
significant differences in rCBF were observed between the two groups. 1-way ANOVA, Bonferroni post hoc test. (B) Assessment of the cerebral
vasculature in wild-type and TAFI-/- mice. A complete Circle of Willis (white arrows) was identified in all animals studied and the distribution of the
MCA trunk and branch appeared to be anatomically identical among the genotypes.
doi:10.1371/journal.pone.0011658.g001
Stroke in TAFI-/- Mice
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Figure 2. TAFI deficiency does not improve outcome after experimental stroke in mice. Infarct size and functional outcome in TAFI-/- mice
and controls (WT, wild-type) 24h after 60 min transient middle cerebral artery occlusion (tMCAO). (A) (top) Representative 2,3,5-
Triphenyltetrazoliumchloride (TTC)-stained coronal brain sections from the two animal groups. Ischemic infarctions appear white and regularly
include the neocortex and basal ganglia as confirmed by hematoxylin and eosin (H&E) staining (bar represents 250 mm, dotted white line indicates
the border between the cortex and the basal ganglia). (bottom) Infarct volumes on day 1 after tMCAO in TAFI-/- mice and controls as determined by
planimetry (n = 11–12/group). Non-parametric Mann Whitney test. (B) Neurological Bederson score and grip test score on day 1 after tMCAO in TAFI-/-
mice and controls. In line with the results on infarct volumes, no significant functional differences became apparent. Non-parametric Mann Whitney
Stroke in TAFI-/- Mice
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Detailed analysis of the functional status also showed no
significant differences between TAFI-/- mice and controls for the
grip test assessing motor function and coordination (3.061.3 vs.
2.460.5; p = 0.05) and for the Bederson score assessing global
neurological function (2.761.1 vs. 3.260.6; p = 0.25) (Figure 2B).
Finally, thrombus formation, i.e. deposition of fibrin(ogen) within
the infarcted cortices of TAFI-/- mice and wild-type mice was
visualized by Western blot (Figure 2C). While fibrin(ogen)
immunoreactivity was largely absent in the non-ischemic contra-
lateral hemispheres, a strong signal was detected in the ischemic
cortices which however, did not differ between the groups.
Discussion
This is the first study examining TAFI-/- mice in an in vivo
model of focal cerebral ischemia. Contrary to our initial
hypothesis, TAFI deficiency did not protect from acute ischemic
stroke.
Existing data strongly support the concept that TAFI acts as a
molecular link between coagulation and fibrinolysis [18]. TAFIa
restrains fibrinolysis through eliminating plasminogen binding sites
from degraded fibrin and direct inhibition of plasminogen
activation [8,9]. Given this prothrombotic mechanism of TAFI
action we assumed that TAFI deficiency would increase
fibrinolysis and consequently, ameliorate ischemic brain damage
after tMCAO in mice, a model in which microvascular thrombosis
and fibrin deposition are key pathophysiological steps [16,19,20].
Another observation indicative for TAFI being an attractive
pharmacological target to treat or prevent thromboembolic
disorders is the absence of excess bleeding in TAFI-/- mice [15].
Such a safe therapy would be particularly advantageous for the
treatment of acute ischemic stroke, where the conventional
thrombolytics and anticoagulants used are inevitably associated
with increased bleeding-related morbidity and mortality.
Whether endogenous fibrinolysis in TAFI-/- mice is indeed
enhanced under pathophysiological conditions in vivo is still under
debate. Nagashima and co-workers found no differences in
occlusion time in TAFI-deficient mice compared to controls after
either artificial arterial or venous injury [15]. Moreover, TAFI
deficiency neither improved the survival rate after thrombin-
induced pulmonary thromboembolism nor in an endotoxin model
of disseminated intravascular coagulation [15]. In contrast, plasma
clots produced from the same knockout mice lysed faster in vitro
and less fibrin was retained in the lungs of TAFI-deficient mice
after batroxobin-induced pulmonary embolism in another study
[21]. We here further extend these findings by demonstrating that
TAFI deficiency has no major beneficial effect on intracerebral
fibrin formation and neuronal damage after ischemic brain
challenge.
Whether our results also apply to the human situation needs
further clarification. Here, plasma TAFI levels were increased in
patients suffering from acute ischemic stroke and correlated with
stroke severity in several retrospective studies [22–26]. A recent
study could establish an association between the Thr325IIe
polymorphism of TAFI with the incidence and age of stroke
onset [27]. However, contradictory reports identifying low TAFI
concentrations as a risk factor for stroke and myocardial infarction
have also been published [28–30]. While excessive TAFI levels
could foster thrombosis by inducing a hypofibrinolytic state, the
inverse association between reduced TAFI concentrations and
higher numbers of thrombotic events might by a consequence of
enhanced inflammation since the anti-inflammatory properties of
TAFI are well established [28,31–33]. The finding that C-reactive
protein (CRP) antigen levels parallel the course of TAFI both in
the acute (increase) and later phase (decrease) of ischemic stroke
further support an association between hemostasis and inflamma-
tion in this disease [25].
Only recently, the safety and efficacy of the direct thrombin
inhibitor dabigatran in preventing systemic embolism including
stroke in patients with atrial fibrillation has been demonstrated
[34, comment in 35]. Interestingly, dagibatran enhances clot
susceptibility to fibrinolysis at least partially by TAFI-dependent
mechanisms in vitro [36]. In line with these findings, TAFIa
significantly affected the efficacy of rt-PA and vessel recanalization
in patients undergoing thrombolysis after acute ischemic stroke
[37] although in vitro experiments suggested that the clot lysis rate
by pharmacological concentrations of rt-PA is not altered by
TAFIa [38].
In summary, despite the definite broad influence of TAFI in the
coagulation-fibrinolysis system, our present study could not
demonstrate a beneficial effect of TAFI deficiency on clot
formation and successive neuronal degeneration after tMCAO
in mice. Whether this also applies to other thrombus-dependent
models of acute ischemic stroke needs to be further established.
Materials and Methods
Animals
A total of 38 mice were used in this study. Animal experiments
were approved by legal state authorities (Bezirksregierung of
Unterfranken, approval number 54-2531.01-25/06) and conduct-
ed according to the recommendations for research in basic stroke
studies [39]. TAFI-/- mice were described previously [40] and
backcrossed more than 10 times to C57Bl/6 background.
Extensive haematological characterization of TAFI-/- mice can
be found elsewhere (review in [14]). Wild-type (WT) C57Bl/6
animals were obtained from Harlan Winkelmann (Borchen,
Germany) and used as controls. Male TAFI-/- and WT mice were
aged 6–8 weeks.
Murine stroke model
Focal cerebral ischemia was induced by 60 min tMCAO as
described [16,17]. Mice were anesthetized with 2.5% isoflurane
(Abbott, Wiesbaden, Germany). Following a midline skin incision
in the neck, the proximal common carotid artery and the external
carotid artery were ligated and a standardized silicon rubber-
coated 6.0 nylon monofilament (60SPPK10; Doccol Corp.,
Redlands, CA, USA) was inserted and advanced via the right
internal carotid artery to occlude the origin of the right MCA.
Operators were blinded to the genotype and operation time per
animal did not exceed 15 minutes. The intraluminal suture was
left in situ for 60 minutes. Then animals were re-anesthetized and
the occluding monofilament was withdrawn to allow reperfusion.
The exclusion criteria were as follows:
a) Death within 24 h after tMCAO
b) Subarachnoid hemorrhage (as macroscopically assessed
during brain sampling)
c) Bederson score = 0 (24 h after tMCAO)
test (C) Accumulation of fibrin(ogen) in the infarcted (+) and contralateral (2) cortices of TAFI-/- mice and controls. Fibrin(ogen) was analyzed by
immunoblotting 24 h after ischemia. Two representative immunoblots of each group are shown.
doi:10.1371/journal.pone.0011658.g002
Stroke in TAFI-/- Mice
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Two animals (14.3%) in the wild-type group and one animal
(7.7%) in the in TAFI-/- group met at least one of these exclusion
criteria and were withdrawn from the study.
Determination of infarct size and histology
Edema-corrected infarct volumes were quantified by planimetry
from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain
sections 24 h after ischemic stroke as described [16,17]. For
morphological assessment, paraffin embedded brains were stained
with hematoxylin and eosin (H&E).
Assessment of functional outcome
24 h after tMCAO the modified Bederson score [41] was used
to determine global neurological function according to the
following scoring system: 0, no deficit; 1, forelimb flexion; 2,
decreased resistance to lateral push; 3, unidirectional circling; 4,
longitudinal spinning; 5, no movement. Motor function and
coordination were evaluated by the grip test [42]. For this test, the
mouse was placed midway on a string between two supports and
rated as follows: 0, falls off; 1, hangs onto string by one or both
forepaws; 2, as for 1, and attempts to climb onto string; 3, hangs
onto string by one or both forepaws plus one or both hindpaws; 4,
hangs onto string by fore- and hindpaws plus tail wrapped around
string; 5, escape (to the supports). Rating was performed in a
blinded manner.
Laser-Doppler flowmetry
Laser-Doppler flowmetry (Moor Instruments, Axminster, U.K.)
was used in some animals (n = 4/group) to monitor rCBF in the
MCA territory (6 mm lateral and 2 mm posterior from bregma)
[43].
Assessment of the cerebral vasculature
For assessment of the cerebral vasculature WT and TAFI-/-
mice (n = 3/group) were deeply anesthetized with CO2 and
transcardially perfused with 4% paraformaldehyde (PFA), followed
by 3 ml black ink diluted in 4% PFA (1:5 v/v). Brains were
carefully removed, fixed in 4% PFA overnight at 4uC and the
Circle of Willis and major arteries were examined under a
microscope.
Protein extraction and Western blot analysis
After TTC staining the cortices were dissected from formalin-
fixed brain slices and homogenized in RIPA buffer (25 mM Tris
pH 7.4, 150 mM NaCl, 1% NP40) containing 2% SDS. The
samples were incubated for 20 minutes at 100uC followed by
incubation at 60uC for 2 hours. Afterwards, tissue lysates were
centrifuged at 15.0006g for 20 minutes at 4uC and supernatants
were used for BCA protein assay and subsequent Western blot
analysis. The total lysates were treated with SDS-PAGE loading
buffer (final conc. 65 mM Tris, 5% 2-mercaptoethanol, 3% SDS,
10% glycerol) at 95uC for 5 minutes. 30 mg of total protein was
electrophoresed and transferred to a PVDF membrane. After
blocking for 1 h with blocking buffer (5% nonfat dry milk, 50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) membranes
were incubated with the primary antibody at 4uC overnight at the
following dilutions: anti-Fibrinogen pAb 1:500 (Acris Antibodies)
and anti-Actin mAb 1:10,000 (Dianova). After a washing step with
TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-
20), membranes were incubated for 1 hour with HRP-conjugated
donkey anti-rabbit IgG (for Fibrinogen) or donkey anti-mouse IgG
(for Actin) at a dilution of 1:5000 and were finally developed using
ECLplus (GE Healthcare).
Statistics
Data are expressed as mean 6 standard deviation (SD). For
statistical analysis, PrismGraph 4.0 software package (La Jolla, CA,
USA) was used. Infarct volumes and neurological scores were
analyzed using the non-parametric Mann Whitney test. Laser
Doppler flowmetry data were compared by Bonferroni-corrected
1-way ANOVA. P-values ,0.05 were considered to be statistically
significant. For power and type-II (beta) error calculations on
infarct volumes GraphPad Stat Mate 2.0 software package was
used (GraphPad Software, Inc, La Jolla, CA, USA). The mean
infarct volume at day 1 after 60 min tMCAO in C57Bl/6 WT
mice was 96627 mm3 and in TAFI-/- mice 91622 mm3 (Fig. 2A).
We assumed that a$35% reduction (Delta = 34.0 mm3) of infarct
size would be of biological relevance [44,45]. The significance
level (alpha) was chosen as 0.05 (two-tailed). Given those premises
the power to detect a difference between means of infarct volumes
of 34.0 mm3 was 90% in our study (type-II [beta] error: 10%)
which is a favourable result compared to many other experimental
stroke studies [39,46].
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